AYTU BIOPHARMA, INC — Form 8-K
Filed November 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 92/100
What the filing says
On November 16, 2026, Aytu BioPharma entered a definitive merger agreement with Rosemont Pharmaceuticals Holdings, Inc., whereby Rosemont will acquire Aytu through a cash tender offer at $2.70 per share, representing approximately $56 million on a fully-diluted basis. The transaction is expected to close by end of calendar 2026, subject to majority shareholder tender and customary closing conditions. Q1 FY2027 results showed net revenue of $14.8M (up 6.9% YoY), EXXUA revenue of $4.9M (up 24.5% sequentially), but net loss of ($3.9)M vs. prior-year net income of $2.0M, with cash declining to $25.5M from $26.3M.
Why this rating
Merger at $56M for ~$7.2M market-cap company represents 7.8x premium; exits shareholders with cash certainty; business-altering event for microcap pharma. EXXUA momentum partially offset by ADHD decline and operating losses.
Tradability signal
NO TRADE
No trade: already up 47.0% on the news and the fade evidence is too weak. Similar past filings (54 in this cell) moved +1.43% in the called direction over 4 hrs; shrunk for sample size that's a +0.98% edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $1.81 ▼ 31.95% | at our read · unknown $2.66 | +10 min · unknown $2.67 ▲ 0.38% | +30 min · unknown $2.66 ▲ 0.00% | +1 hr · unknown $2.66 ▲ 0.00% | +4 hrs · unknown $2.65 ▼ 0.19% |
The stock had already moved +46.96% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.